MALVERN, PA — Endo, Inc. (OTCQX: NDOI) has announced the start of shipments for its doxycycline for injection, USP 100 mg/vial, a generic alternative to DOXY 100™. This marks a significant expansion of the company’s sterile injectable product line.
The AP-rated doxycycline offering provides healthcare providers and hospital pharmacies with a cost-effective alternative for treating infections requiring intravenous antibiotic therapy. The move is expected to enhance access to a trusted treatment option in hospital settings.
“We’re pleased to provide choices to healthcare providers and hospital pharmacies as they work to deliver quality patient care,” said Scott Sims, Senior Vice President and General Manager, Injectable Solutions & Generics at Endo. “The doxycycline for injection strengthens our sterile injectable product portfolio and underscores our reputation as a reliable supplier of aseptic medicines.”
With this launch, Endo aims to capture a share of the growing demand for generic injectables while supporting the needs of healthcare systems nationwide.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.